Share This Page
Drugs in ATC Class L02AB
✉ Email this page to a colleague
Drugs in ATC Class: L02AB - Progestogens
| Tradename | Generic Name |
|---|---|
| LUNELLE | estradiol cypionate; medroxyprogesterone acetate |
| MEGACE | megestrol acetate |
| MEGACE ES | megestrol acetate |
| MEGESTROL ACETATE | megestrol acetate |
| >Tradename | >Generic Name |
Showing 1 to 4 of 4 entries
L02AB Market Analysis and Financial Projection
The market dynamics and patent landscape for ATC Class L02AB (Progestogens) reflect a rapidly evolving sector driven by therapeutic innovations, expanding applications, and strategic intellectual property developments. Here’s a detailed analysis:
Market Dynamics
Growth Projections and Segmentation
- The global progesterone market is projected to grow from $1.68 billion in 2025 to $3.15 billion by 2030 at a CAGR of 13.5%[4]. This growth is fueled by advancements in oncology, hormonal therapies, and non-therapeutic applications (e.g., anti-aging cosmetics)[4].
- Cancer cachexia treatment is a major driver, where progestogens dominate with 57.4% market share due to their efficacy in appetite stimulation and weight stabilization[11][17]. The segment is projected to grow at a 5.4% CAGR through 2032[17].
- Segmentation:
- By type: Ulipristal acetate and mifepristone are key synthetic variants[1].
- By application: Hospitals and endocrinology departments account for significant usage, driven by cancer and reproductive health treatments[1].
Competitive Landscape
- Top players include Bayer, Pfizer, and Gedeon Richter, which focus on expanding portfolios through R&D and strategic partnerships[1][4].
- Emerging trends:
- Combination therapies: Integrate progestogens with nutritional support and anti-inflammatory agents for cancer cachexia[11][14].
- Biosimilars: Over 50 biosimilars (e.g., insulin lispro, trastuzumab) have entered markets, increasing accessibility[3].
Patent Landscape
Key Innovations and Filings
- Synthetic progestogens: Patents like US-11439598-B2 highlight novel compounds (e.g., 21,17-carbolactone derivatives) for contraceptive and oncologic use[2][16].
- Therapeutic expansions:
- US11413249B2 covers drospirenone-based contraceptives with improved safety profiles[16].
- Anticancer applications: Progestogens like megestrol are patented for antiproliferative effects in breast cancer[10].
Regional Patent Activity
- North America: Leads with 700+ patents focused on smart drug delivery and material innovations[7].
- Europe: Emphasizes eco-friendly formulations and compliance with strict regulatory standards[7].
- Asia-Pacific: Rapid growth in non-hormonal alternatives and cost-effective generics[7].
Regulatory and Clinical Drivers
- ATC Classification: Progestogens under L02AB are specifically classified for cancer treatment (e.g., breast, prostate), with defined daily doses (DDDs) standardized for global utilization[5][15].
- Clinical demand: Rising cancer incidence (e.g., 18.1 million new cases in 2018) and cachexia prevalence (affecting ~50% of cancer patients) underpin market expansion[14][17].
Challenges
- Biosimilar competition: Pressures pricing for branded progestogens[3].
- Regulatory complexity: Varied approval processes delay market entry for new formulations[4].
- R&D costs: High investment required for targeted therapies and combination regimens[11].
Regional Insights
- North America: Holds 45% market share due to advanced healthcare infrastructure and high R&D expenditure[17].
- Asia-Pacific: Fastest-growing region, driven by improving healthcare access and rising cancer rates[4][17].
Key Takeaways
- Progestogens under L02AB are pivotal in oncology and metabolic care, with a robust pipeline of synthetic variants and biosimilars.
- Patent strategies focus on drug delivery innovations and combination therapies to sustain competitive advantage.
- Market growth will hinge on addressing unmet needs in emerging economies and navigating biosimilar competition.
Highlight: "Progestogens’ versatility in treating cancer cachexia and hormonal disorders ensures their enduring dominance in therapeutic markets"[11][14].
References
- https://www.biospace.com/estrogen-and-progesterone-market-size-share-growth-analysis-trend-and-forecast-research-report-by-2027
- https://pubchem.ncbi.nlm.nih.gov/patent/US11439598
- https://reports.helsana.ch/wp-content/uploads/2022/11/Helsana-Arzneimittelreport-2022.pdf
- https://www.360iresearch.com/library/intelligence/progesterone
- https://atcddd.fhi.no/atc_ddd_index/?code=L02AB03
- https://www.zva.gov.lv/sites/default/files/2017-12/zva-zstat-2016.pdf
- https://www.globenewswire.com/news-release/2025/03/07/3039078/0/en/Contraceptive-Devices-Patent-Landscape-Report-2023-2024-2032-Innovations-in-Materials-Smart-Monitoring-and-Eco-friendly-Methods.html
- https://vvkt.lrv.lt/media/viesa/saugykla/2023/9/nvNsI8S7K9U.pdf
- https://vvkt.lrv.lt/media/viesa/saugykla/2023/9/09vLW9zMlcw.pdf
- https://pubmed.ncbi.nlm.nih.gov/20519331/
- https://www.vantagemarketresearch.com/industry-report/cancer-cachexia-market-2526
- https://pmc.ncbi.nlm.nih.gov/articles/PMC8076393/
- https://www.genome.jp/kegg-bin/search_brite?catalog=brite.list&search_string=RELA&option=-n
- https://www.knowledge-sourcing.com/report/cancer-cachexia-market
- https://atcddd.fhi.no/atc_ddd_index/?showdescription=yes&code=L02AB
- https://patents.google.com/patent/US11413249B2/en
- https://market.us/report/cancer-cachexia-market/
- https://www.fortunebusinessinsights.com/cancer-cachexia-market-103262
More… ↓
